<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Headache Pain</journal-id><journal-id journal-id-type="iso-abbrev">J Headache Pain</journal-id><journal-title-group><journal-title>The Journal of Headache and Pain</journal-title></journal-title-group><issn pub-type="ppub">1129-2369</issn><issn pub-type="epub">1129-2377</issn><publisher><publisher-name>Springer Milan</publisher-name><publisher-loc>Milan</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23054063</article-id><article-id pub-id-type="pmc">3484257</article-id><article-id pub-id-type="publisher-id">484</article-id><article-id pub-id-type="doi">10.1007/s10194-012-0484-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Trials</subject></subj-group></article-categories><title-group><article-title>Comparison of tolerability and efficacy of a combination of paracetamol&#x000a0;+&#x000a0;caffeine and sumatriptan in the treatment of migraine attack: a randomized, double-blind, double-dummy, cross-over study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pini</surname><given-names>Luigi Alberto</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Guerzoni</surname><given-names>Simona</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Cainazzo</surname><given-names>Michela</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ciccarese</surname><given-names>Michela</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Prudenzano</surname><given-names>Maria Pia</given-names></name><address><email>m.p.prudenzano@neurol.uniba.it</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Livrea</surname><given-names>Paolo</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label>Headache Study Center, University of Modena &#x00026; Reggio Emilia, Modena, Italy </aff><aff id="Aff2"><label>2</label>Headache Center, &#x0201c;L. Amaducci&#x0201d; Neurological Clinic, University of Bari, Bari, Italy </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>10</month><year>2012</year></pub-date><pub-date pub-type="pmc-release"><day>2</day><month>10</month><year>2012</year></pub-date><pub-date pub-type="ppub"><month>11</month><year>2012</year></pub-date><volume>13</volume><issue>8</issue><fpage>669</fpage><lpage>675</lpage><history><date date-type="received"><day>29</day><month>7</month><year>2012</year></date><date date-type="accepted"><day>2</day><month>9</month><year>2012</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2012</copyright-statement></permissions><abstract id="Abs1"><p>In this study, we compared the efficacy and tolerability of the combination of paracetamol 1,000&#x000a0;mg&#x000a0;+&#x000a0;caffeine 130&#x000a0;mg (PCF) with sumatriptan 50&#x000a0;mg (SUM) in migraine attacks. This was a multi-center randomized double-blind, double-dummy, cross-over controlled trial. The efficacy was assessed by the sum of pain intensity differences, the curve of mean pain intensity, the number of pain free at 2&#x000a0;h, and the total pain relief. Tolerability was assessed by recording adverse events within 4&#x000a0;h after drug assumption and evaluating the global judgement of patients. The comparison of these parameters did not show differences between the two drugs which resulted absolutely overlapping in pain relief and patients evaluation. In conclusion, we confirm the efficacy and safety of PCF such as SUM in the treatment of migraine attacks.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Migraine</kwd><kwd>Acute treatment</kwd><kwd>Paracetamol&#x02013;caffeine combination</kwd><kwd>Sumatriptan</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2012</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Migraine is an intermittent neurological disorder, affecting 10&#x02013;12&#x000a0;% of the western population. In population studies, the prevalence of migraine is approximately 17&#x000a0;% in women and 6&#x000a0;% in men [<xref ref-type="bibr" rid="CR1">1</xref>]. Migraine is a common, disabling headache disorder, with considerable social and economic impact, and is currently ranked by the World Health Organization as 19th among causes of years lived with disability [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>].</p><p>Migraine is diagnosed according to the criteria of the International Headache Society (IHS) as a recurrent headache disorder manifesting with attacks lasting 4&#x02013;72&#x000a0;h. Typical characteristics of the migraine headache are unilateral location, pulsating quality, moderate or severe intensity, aggravation by routine physical activity, and association with nausea and/or photophobia, and phonophobia [<xref ref-type="bibr" rid="CR4">4</xref>].</p><p>Acute migraine attacks can be treated with either unspecific drugs such as acetyl salicylic acid and NSAIDs or specific medicines like triptans and ergot alkaloids. In addition, prokinetic drugs and neuroleptics may be useful [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>]. Triptans are migraine-specific drugs binding to serotonergic receptors. They are considered first-line therapy for moderate-severe migraine, or mild-moderate attacks unresponsive to nonspecific analgesics [<xref ref-type="bibr" rid="CR7">7</xref>]. Triptans are more effective in injectable than in oral formulations and should be avoided in patients with a risk for vascular complication [<xref ref-type="bibr" rid="CR7">7</xref>]. NSAIDs such as ketorolac and naproxen have the advantage of being appropriate for patients with vascular risk factors and they do not cause sedation [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. NSAIDs are generally well tolerated and may provide benefit even when given late in the migraine attack [<xref ref-type="bibr" rid="CR8">8</xref>]. However, gastric irritation and occasionally ulceration may complicate treatment with aspirin or other NSAIDs, even when they are used intermittently [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. The combination of paracetamol and metoclopramide was showed to be superior to paracetamol alone in migraine [<xref ref-type="bibr" rid="CR9">9</xref>], Paracetamol&#x000a0;+&#x000a0;caffeine is an useful alternative to NSAID for tension-type headache (TTH); it was compared with placebo in three high-quality studies, showing its superiority over placebo as well as a good tolerability [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>].</p><p>Till date there is only a large-scale study comparing the early treatment of an association of migraine of sumatriptan 50&#x000a0;mg and a combination of aspirin&#x000a0;+&#x000a0;acetaminophen&#x000a0;+&#x000a0;caffeine [<xref ref-type="bibr" rid="CR12">12</xref>]. This study has been discussed by some authors for some methodological criticisms [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Studies comparing paracetamol&#x000a0;+&#x000a0;caffeine versus sumatriptan at low dose for the treatment of mild-severe migraine treatment are lacking.</p><p>The aim of this study was to evaluate the association of paracetamol 1,000&#x000a0;mg&#x000a0;+&#x000a0;caffeine 130&#x000a0;mg (PCF) to treat acute migraine attacks and compare the efficacy and safety of this product with a gold standard sumatriptan 50&#x000a0;mg by mouth.</p></sec><sec id="Sec2" sec-type="methods"><title>Patients and methods</title><sec id="Sec3"><title>Patients</title><p>This multi-center study was conducted between May 2011 and April 2012 in two Italian Headache Centers recruiting 108 outpatient volunteers of both genders (one-third male, age 18&#x02013;62) with a clinical history of episodic migraine fulfilling the following inclusion criteria:<list list-type="bullet"><list-item><p>Diagnosis of migraine fulfilling ICHD-II criteria for migraine with or without aura.</p></list-item><list-item><p>Mean frequency of 2&#x02013;8 attacks per month.</p></list-item><list-item><p>If female, adequate contraception in women of fertile age.</p></list-item><list-item><p>Daily consumption of at least two cups of coffee.</p></list-item><list-item><p>Medical history and clinical parameters inconsistent with organic or psychiatric disorders associated with headaches.</p></list-item></list></p><p>Exclusion criteria were:<list list-type="bullet"><list-item><p>Declared hypersensitivity or allergy to paracetamol or sumatriptan.</p></list-item><list-item><p>Presence of chronic migraine or headache, or medication overuse headache.</p></list-item><list-item><p>Post-traumatic headache.</p></list-item><list-item><p>Past or present earth ischemia or myocardial infarction, cerebral ischemic attacks, peripheral vascular diseases, hepatic or renal diseases, mail, severe or uncontrolled hypertension, phenylketonuria, hemolytic anemia.</p></list-item><list-item><p>Treatment with anticoagulants or antiplatelet drugs.</p></list-item><list-item><p>Drugs and alcohol abuse, or psychiatric diseases.</p></list-item><list-item><p>Coagulation disorders, peptic ulcer disease, pancreatic disease, clinically significant renal or hepatic disease, blood hypertension, mild/moderate kidney or liver failure, Gilbert&#x02019;s syndrome.</p></list-item></list></p><p>The study was conducted, following good clinical practice standards and in accordance with the Declaration of Helsinki (Tokyo version 2004) and stated after independent ethics committee approval for each investigator (Paracaf-emi-010 Code EudraCt 2010-019083-36). Prior to enrolment the patients gave their written informed consent; they were allowed to terminate participation in the trial at any time, without giving reasons. This trial complies with the guidelines for trials of drug treatments in migraine of the IHS [<xref ref-type="bibr" rid="CR15">15</xref>].</p></sec><sec id="Sec4"><title>Study design and treatments</title><p>Primary objectives of the study were to show the <italic>efficacy</italic> of the association of paracetamol 1,000&#x000a0;mg and caffeine 130&#x000a0;mg in reducing pain in migraine attacks, and the <italic>tolerability</italic> of this combination in migraine treatment. Secondary objective was to demonstrate the non-inferiority of the PCF association versus SUM in a comparison between these two treatment in migraine attacks.</p><p>This was a phase IV study randomized, double-dummy, cross-over, drug-controlled trial. We decided to exclude placebo due to some ethical reasons: this a phase IV study, comparing two well-known active drugs, and our ethical committee did not allow private patients of an active treatment in a study aimed to compare two active drugs.</p><p>After obtaining the signature on the informed consent form, the patients were required to treat three subsequent consecutive migraine attacks with the investigational study medications, according to a randomized cross-over sequence computer generated using Microsoft_Access 2003. Each patient was randomly allocated to assume either one PCF and two SUM, or two PCF and one SUM in a randomized sequence treatment. Eligible patients were assigned in sequential order of entry. Access to the randomisation code was strictly controlled and the treatment assignment remained unknown to all parties involved in the trial until database formal lock.</p><p>Subjects in all treatment groups received three identical boxes (numbered progressively from 1 to 3, to indicate the exact order in which they should have been used) containing: one soft gel capsule containing one tablet of placebo or sumatriptan 50&#x000a0;mg and one sachet containing paracetamol 1,000&#x000a0;mg&#x000a0;+&#x000a0;caffeine 130&#x000a0;mg or one sachet containing the excipients and flavor as the active drug.</p><p>Blinding was ensured using matched trial supplies, identical in color, size, shape, and taste. At each migraine attack patients would have to take one soft gel capsule and one sachet at the same time. The trial medication was to be taken when the headache occurred, and when the patients would normally have taken their usual analgesic. Other than study medication, patients received rescue medication (usual medication for each patient), to be taken 3&#x000a0;h after the administration of the trial medication, if the pain lasted over the 2&#x000a0;h.</p><p>At baseline visit, a complete patients&#x02019; medical history and concomitant treatments were recorded, vital signs were measured, and a physical examination was performed by the investigator. Patients were required to record in a headache diary, the date and time of drug ingestion, pain intensity before treatment, pain intensity, pain relief, and adverse events (AEs) after treatment recorded at 1, 2, 3, 4, and 24&#x000a0;h. At the end of 4-h measurement interval or at the time of use of rescue medication, the patients had to record the presence and intensity of AEs. A global judgment of the treatment was also required. The same procedures were repeated for the two subsequent migraine attacks.</p></sec><sec id="Sec5"><title>Outcomes</title><p>Safety and tolerability were evaluated by comparing vital signs at screening and final visits and by recording AEs. AEs could be recorded by the investigator or by the patient filling in a symptom check-list (including nervousness, palpitation, insomnia, dizziness, abdominal pain, dyspepsia, nausea, vomiting, drowsiness, and fatigue) hourly for 4&#x000a0;h after the study medication ingestion. AEs severity was determined by subjective evaluation of the patient and classified as mild (signs or symptoms easily tolerated), moderate (discomfort sufficient to cause interference with normal activities), and severe (incapacitating with inability to do work or undertake normal activity).</p><p>A global assessment of tolerability was expressed by the patient, using a 5-point verbal rating scale (VRS: &#x02018;excellent&#x02019;, &#x02018;very good&#x02019;, &#x02018;good&#x02019;, &#x02018;sufficient&#x02019;, and &#x02018;poor&#x02019;).</p><p>To assess treatments&#x02019; efficacy, intensity of pain (on a 4-point scale: 0 &#x02018;absent&#x02019;, 1 &#x02018;mild&#x02019;, 2 &#x02018;moderate&#x02019;, 3 &#x02018;severe&#x02019;) and pain relief (on a 5-point scale: 0 &#x02018;no relief&#x02019;, 1 &#x02018;little relief&#x02019;, 2 &#x02018;some relief&#x02019;, 3 &#x02018;much relief&#x02019;, 4 &#x02018;complete relief&#x02019;) were evaluated hourly during the 4-h post-dose period.</p><p>Based on these two variables, the following parameters were calculated:<list list-type="bullet"><list-item><p>For each patients the sum of pain intensity differences (SPID) was calculated as the sum of differences between pre-dose assessment and every post-dose assessment.</p></list-item><list-item><p>Total pain relief (TOTPAR), calculated as the sum of every post-dose assessment.</p></list-item></list></p></sec><sec id="Sec6"><title>Statistical analysis</title><p>Migraine is a disease with a large inter-individual variability to treatment; to reduce this bias the trial is conducted following a double-blind controlled double-dummy cross-over study versus an active drug.</p><p>The study was powered to test the primary hypothesis, namely that paracetamol 1,000&#x000a0;mg&#x000a0;+&#x000a0;caffeine 130&#x000a0;mg would be non-inferior to SUM as regards the proportion of patients within the 4-h post-dose period.</p><p>Assuming a reduction of pain intensity, calculated in a 4-point scale, as recommended by IHS, within 4&#x000a0;h as 1.2&#x000a0;&#x000b1;&#x000a0;1.3 (SD) in the control study group, we assumed that PCF will be non-inferior when the mean will be &#x00394;&#x000a0;=&#x000a0;&#x000b1;0.5. Giving an unilateral &#x003b1;&#x000a0;=&#x000a0;0.025 and a 80&#x000a0;% power 110 case for treatment will be enough for statistical analysis.</p><p>According to study protocol all the randomized patients who took at least one of the treatments (intention-to-treat, ITT) were evaluated.</p><p>Data missing for any scheduled evaluation was replaced by the last observation carried forward (LOCF) procedure. The tolerability endpoints were evaluated using ITT populations; ITT population was employed for efficacy analyses. Descriptive statistics on population was used for demographic and baseline characteristics.</p><p>The Fisher exact test (with a 90&#x000a0;% confidence interval) was used to compare the percentage of patients who recorded AEs after each treatment. Besides those recorded by patients in the 4-h post-dose period, all the AEs were classified by the investigator on the basis of treatment received, system involved, severity, and correlation with the investigational medication. The analysis of variance was used to evaluate the differences of vital signs respect to baseline.</p><p>The analysis of variance was used to evaluate SPID and TOTPAR. The patient&#x02019; preference for one of the treatments was reported as a distribution of frequency. Other statistical tests were used when appropriate.</p></sec></sec><sec id="Sec7" sec-type="results"><title>Results</title><p>108 caucasian patients participated in the study and 92 took at least one of the treatment, whereas 16 patients who filled inclusion criteria did not take any medication. In three cases, the subjects in the following days after randomization explicitly refused to continue the study; In the other 13 cases, when the patients where recalled after 2&#x000a0;months for the second scheduled visit, they refused to continue the protocol for personal reasons. Two patients assumed one treatment and eight subjects assumed two treatments; so the ITT population was of 92 cases and were evaluated for efficacy and tolerability for both the treatments. Globally 264 migraine attacks were evaluated, 131 treated with PCF and 133 treated with SUM. The demographic characteristics and headache history of the patients are summarized in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Demographic data and headache history (ITT, <italic>n</italic>&#x000a0;=&#x000a0;92)</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left">Male</td><td align="left">31 (33.6&#x000a0;%)</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Female</td><td align="left">61 (66.3&#x000a0;%)</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Age (years) (mean&#x000a0;&#x000b1;&#x000a0;SD)</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Male</td><td align="left">33.6&#x000a0;&#x000b1;&#x000a0;10.5</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Female</td><td align="left">35.6&#x000a0;&#x000b1;&#x000a0;9.6</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Headache Index</td><td align="left">4&#x000a0;&#x000b1;&#x000a0;3.5</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="5">Usual pain intensity</td></tr><tr><td align="left">&#x000a0;Mild</td><td align="left">20 (22&#x000a0;%)</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Moderate</td><td align="left">49 (53&#x000a0;%)</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Severe</td><td align="left">23 (25&#x000a0;%)</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">BMI</td><td align="left">&#x0003c;18.5</td><td align="left">18.5&#x02013;24.9</td><td align="left">25.0&#x02013;29.9</td><td align="left">&#x0003e;30</td></tr><tr><td align="left">Male (%)</td><td align="left">&#x02013;</td><td align="left">46.2</td><td align="left">46.2</td><td align="left">7.7</td></tr><tr><td align="left">Female (%)</td><td align="left">5.9</td><td align="left">78.4</td><td align="left">11.8</td><td align="left">3.9</td></tr></tbody></table><table-wrap-foot><p>Headache index&#x000a0;=&#x000a0;number of day with headache in the observed period</p><p>Pain intensity&#x000a0;=&#x000a0;in a 0&#x02013;3 scale</p></table-wrap-foot></table-wrap></p><p>With regard to the familial history, 66 (72&#x000a0;%) of cases referred a first-order relative suffering from headache.</p><sec id="Sec8"><title>Efficacy</title><p>The comparison between the two treatments did not show any difference in pain intensity at baseline both as absolute values and for a Chi square test (<italic>p</italic>&#x000a0;=&#x000a0;0.72).</p><p>Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> reports the time course of mean pain intensity for PCF and SUM treatment, while the sum of SPID and the TOTPAR in the <italic>T</italic> 0&#x02013;4&#x000a0;h period is illustrated in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. <fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Time course of pain intensity. In both treatment groups since at time <italic>T</italic>&#x000a0;<italic>=</italic>&#x000a0;1&#x000a0;h in both groups there was a highly significant difference versus basal time (paired <italic>t</italic> test: <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001)</p></caption><graphic xlink:href="10194_2012_484_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Sum of pain intensity differences (SPID) and total pain relief (TOTPAR) in the 4-h observation period for the ITT dataset (<italic>n</italic>&#x000a0;=&#x000a0;264)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">PCF</th><th align="left">SUM</th><th align="left">All</th><th align="left"><italic>t</italic> test</th></tr></thead><tbody><tr><td align="left" colspan="5">SPID</td></tr><tr><td align="left">&#x000a0;Baseline intensity</td><td char="." align="char">2.1&#x000a0;&#x000b1;&#x000a0;0.7</td><td char="." align="char">2.1&#x000a0;&#x000b1;&#x000a0;0.8</td><td char="." align="char">2.1&#x000a0;&#x000b1;&#x000a0;0.8</td><td align="left"/></tr><tr><td align="left">&#x000a0;Mean&#x000a0;&#x000b1;&#x000a0;SD</td><td char="." align="char">3.2&#x000a0;&#x000b1;&#x000a0;3.8</td><td char="." align="char">3.2&#x000a0;&#x000b1;&#x000a0;3.7</td><td char="." align="char">3.2&#x000a0;&#x000b1;&#x000a0;3.8</td><td char="." align="char"><italic>p</italic>&#x000a0;=&#x000a0;0.88</td></tr><tr><td align="left" colspan="5">TOTPAR</td></tr><tr><td align="left">&#x000a0;Mean&#x000a0;&#x000b1;&#x000a0;SD</td><td char="." align="char">7.0&#x000a0;&#x000b1;&#x000a0;3.6</td><td char="." align="char">7.4&#x000a0;&#x000b1;&#x000a0;3.6</td><td char="." align="char">7.2&#x000a0;&#x000b1;&#x000a0;3.6</td><td char="." align="char"><italic>p</italic>&#x000a0;=&#x000a0;0.48</td></tr></tbody></table><table-wrap-foot><p><italic>SD</italic> standard deviation</p><p>ANOVA for SPID and TOTPAR showed a positive independent significant variable for intensity of headache at baseline (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001), while no difference between type of treatment (<italic>p</italic>&#x000a0;=&#x000a0;0.8849)</p></table-wrap-foot></table-wrap></p><p>Data showed that both the treatments are effective with respect to the baseline, but there were no differences between the treatments.</p><p>The time course of TOTPAR is reported in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>, where similar results are showed. Rescue medication was assumed in 38&#x000a0;% of PCF treatments and 45&#x000a0;% of SUM treatment, without significant differences (Fisher exact test: <italic>p</italic>&#x000a0;=&#x000a0;0.3308), even looking at the timing of assumption, i.e., before or 3&#x000a0;h after the first treatment (Fisher exact test: <italic>p</italic>&#x000a0;=&#x000a0;0.2245).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Time course of the total pain relief (TOTPAR) in the ITT dataset. In both treatment groups, since time <italic>T</italic>&#x000a0;<italic>=</italic>&#x000a0;0&#x02013;1&#x000a0;h there was a highly significant difference versus basal time (paired <italic>t</italic> test: <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001)</p></caption><graphic xlink:href="10194_2012_484_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec9"><title>Safety</title><p>Taking into account the ITT population and the 264 considered attacks, the number of side effects is reported in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>. In about half of recorded attacks, we did not register adverse events (0.9&#x000a0;&#x000b1;&#x000a0;1.2 and 1.1&#x000a0;&#x000b1;&#x000a0;1.3 for PCF and SUM, respectively), without differences between the treatments (<italic>t</italic> test: <italic>p</italic>&#x000a0;=&#x000a0;0.156). The intensity of side effects was always slight or moderate, all side effects disappeared spontaneously and none requested any modification of scheduled treatment. The only difference between the treatments was a slight increase of referred fatigue in patients assuming SUM.<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Assessment of efficacy and tolerability for each treatment (<italic>n</italic>&#x000a0;=&#x000a0;264)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">PCF, <italic>n</italic> (%)</th><th align="left">SUM, <italic>n</italic> (%)</th></tr></thead><tbody><tr><td align="left">Efficacy</td><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Complete relief</td><td char="(" align="char">97 (74.1)</td><td char="(" align="char">96 (72.2)</td></tr><tr><td align="left">&#x000a0;Much relief</td><td char="(" align="char">8 (6.5)</td><td char="(" align="char">9 (6.7)</td></tr><tr><td align="left">&#x000a0;Some relief</td><td char="(" align="char">7 (5.3)</td><td char="(" align="char">8 (6.1)</td></tr><tr><td align="left">&#x000a0;Little</td><td char="(" align="char">8 (6.5)</td><td char="(" align="char">9 (6.7)</td></tr><tr><td align="left">&#x000a0;No relief</td><td char="(" align="char">11 (8.4)</td><td char="(" align="char">11 (8.3)</td></tr><tr><td align="left" colspan="3">Tolerability</td></tr><tr><td align="left">&#x000a0;Excellent</td><td char="(" align="char">53 (40.4)</td><td char="(" align="char">48 (36.4)</td></tr><tr><td align="left">&#x000a0;Very good</td><td char="(" align="char">34 (26.2)</td><td char="(" align="char">33 (24.6)</td></tr><tr><td align="left">&#x000a0;Good</td><td char="(" align="char">16 (12.2)</td><td char="(" align="char">24 (17.8)</td></tr><tr><td align="left">&#x000a0;Sufficient</td><td char="(" align="char">17 (12.8)</td><td char="(" align="char">15 (11.5)</td></tr><tr><td align="left">&#x000a0;Poor</td><td char="(" align="char">11 (8.4)</td><td char="(" align="char">13 (9.7)</td></tr></tbody></table><table-wrap-foot><p>Fisher exact test <italic>p</italic>&#x000a0;=&#x000a0;0.98 for efficacy and <italic>p</italic>&#x000a0;=&#x000a0;0.43 for tolerability</p></table-wrap-foot></table-wrap></p><p>In Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> the global assessment of efficacy and tolerability is referred as reported by patients. In Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref> the number of side effects is reported, and in Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref> the types of side effects recorded are reported.<table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Number of adverse events recorded after drug assumption (dataset&#x000a0;=&#x000a0;92 patients and 264 treatments)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3">Adverse events</th><th align="left" rowspan="2" colspan="2">Total</th><th align="left" colspan="4">Treatments</th></tr><tr><th align="left" colspan="2">PCF</th><th align="left" colspan="2">SUM</th></tr><tr><th align="left"><italic>N</italic></th><th align="left">%</th><th align="left"><italic>N</italic></th><th align="left">%</th><th align="left"><italic>N</italic></th><th align="left">%</th></tr></thead><tbody><tr><td align="left">0 (none)</td><td char="." align="char">125</td><td char="." align="char">47.3</td><td char="." align="char">69</td><td char="." align="char">52.7</td><td char="." align="char">56</td><td char="." align="char">42.1</td></tr><tr><td align="left">1</td><td char="." align="char">72</td><td char="." align="char">27.2</td><td char="." align="char">32</td><td char="." align="char">24.5</td><td char="." align="char">40</td><td char="." align="char">30.1</td></tr><tr><td align="left">2</td><td char="." align="char">40</td><td char="." align="char">15.1</td><td char="." align="char">18</td><td char="." align="char">13.6</td><td char="." align="char">22</td><td char="." align="char">16.5</td></tr><tr><td align="left">3</td><td char="." align="char">10</td><td char="." align="char">3.9</td><td char="." align="char">4</td><td char="." align="char">2.7</td><td char="." align="char">6</td><td char="." align="char">4.5</td></tr><tr><td align="left">4</td><td char="." align="char">14</td><td char="." align="char">5.3</td><td char="." align="char">8</td><td char="." align="char">6.4</td><td char="." align="char">6</td><td char="." align="char">4.5</td></tr><tr><td align="left">5</td><td char="." align="char">2</td><td char="." align="char">0.8</td><td char="." align="char"/><td align="left"/><td char="." align="char">2</td><td char="." align="char">1.6</td></tr><tr><td align="left">6</td><td char="." align="char">1</td><td char="." align="char">0.4</td><td char="." align="char"/><td align="left"/><td char="." align="char">1</td><td char="." align="char">0.7</td></tr><tr><td align="left">Total</td><td char="." align="char">264</td><td char="." align="char">100.0</td><td char="." align="char">131</td><td char="." align="char">100.0</td><td char="." align="char">133</td><td char="." align="char">100.0</td></tr></tbody></table><table-wrap-foot><p><italic>t</italic> test: <italic>p</italic>&#x000a0;=&#x000a0;0.156, between treatments</p></table-wrap-foot></table-wrap><table-wrap id="Tab5"><label>Table&#x000a0;5</label><caption><p>Types of adverse events reported by patients (<italic>N</italic>&#x000a0;=&#x000a0;92; 264 treatments)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3"/><th align="left" rowspan="2" colspan="2">Total (<italic>n</italic>&#x000a0;=&#x000a0;264)</th><th align="left" colspan="4">Treatment</th><th align="left" rowspan="3">Fisher exact test (<italic>p</italic>)</th></tr><tr><th align="left" colspan="2">PCF (<italic>n</italic>&#x000a0;=&#x000a0;131)</th><th align="left" colspan="2">SUM (<italic>n</italic>&#x000a0;=&#x000a0;133)</th></tr><tr><th align="left"><italic>N</italic></th><th align="left">%</th><th align="left"><italic>N</italic></th><th align="left">%</th><th align="left"><italic>N</italic></th><th align="left">%</th></tr></thead><tbody><tr><td align="left">None</td><td char="." align="char">125</td><td char="." align="char">47.3</td><td char="." align="char">69</td><td char="." align="char">52.7</td><td char="." align="char">56</td><td char="." align="char">42.1</td><td align="left"/></tr><tr><td align="left">Nervousness</td><td char="." align="char">32</td><td char="." align="char">12.2</td><td char="." align="char">13</td><td char="." align="char">10.0</td><td char="." align="char">19</td><td char="." align="char">14.3</td><td char="." align="char">0.4125</td></tr><tr><td align="left">Palpitazion</td><td char="." align="char">27</td><td char="." align="char">10.4</td><td char="." align="char">12</td><td char="." align="char">9.1</td><td char="." align="char">15</td><td char="." align="char">11.6</td><td char="." align="char">0.6607</td></tr><tr><td align="left">Insomnia</td><td char="." align="char">11</td><td char="." align="char">4.1</td><td char="." align="char">6</td><td char="." align="char">4.5</td><td char="." align="char">5</td><td char="." align="char">3.6</td><td char="." align="char">0.7471</td></tr><tr><td align="left">Dizziness</td><td char="." align="char">12</td><td char="." align="char">4.5</td><td char="." align="char">4</td><td char="." align="char">2.7</td><td char="." align="char">8</td><td char="." align="char">6.3</td><td char="." align="char">0.3326</td></tr><tr><td align="left">Abdominal pain</td><td char="." align="char">12</td><td char="." align="char">4.5</td><td char="." align="char">3</td><td char="." align="char">1.8</td><td char="." align="char">9</td><td char="." align="char">7.1</td><td char="." align="char">0.1016</td></tr><tr><td align="left">Dyspepsia</td><td char="." align="char">21</td><td char="." align="char">8.1</td><td char="." align="char">11</td><td char="." align="char">7.4</td><td char="." align="char">12</td><td char="." align="char">8.9</td><td char="." align="char">0.8067</td></tr><tr><td align="left">Nausea</td><td char="." align="char">67</td><td char="." align="char">25.2</td><td char="." align="char">37</td><td char="." align="char">28.2</td><td char="." align="char">30</td><td char="." align="char">22.3</td><td char="." align="char">0.3553</td></tr><tr><td align="left">Vomito</td><td char="." align="char">6</td><td char="." align="char">2.3</td><td char="." align="char">4</td><td char="." align="char">2.7</td><td char="." align="char">2</td><td char="." align="char">1.8</td><td char="." align="char">0.6818</td></tr><tr><td align="left">Drowsiness</td><td char="." align="char">42</td><td char="." align="char">15.8</td><td char="." align="char">18</td><td char="." align="char">13.6</td><td char="." align="char">24</td><td char="." align="char">17.9</td><td char="." align="char">0.4625</td></tr><tr><td align="left">Fatigue</td><td char="." align="char">27</td><td char="." align="char">10.4</td><td char="." align="char">7</td><td char="." align="char">5.5</td><td char="." align="char">20</td><td char="." align="char">15.1</td><td char="." align="char">0.0260</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="Sec10" sec-type="discussion"><title>Discussion</title><p>Migraine is a widespread condition that in the majority of cases is self-treated by patients, so the use of safe and effective drugs is a reasonable basis for selecting medicines.</p><p>Many studies have been conducted to show the efficacy of combination drugs in the treatment of migraine attacks [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>].</p><p>In a three double-blind, randomized, parallel-group, single-dose, placebo-controlled studies Lipton showed that the combination of acetaminophen, aspirin, and caffeine was highly effective for the treatment of migraine headache pain as well as for alleviating the nausea, photophobia, phonophobia, and functional disability associated with migraine attacks. This drug combination also has an excellent safety profile and is well tolerated [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p>In 2005, Goldstein compared a combination of non-prescription migraine medication (acetaminophen 500&#x000a0;mg, aspirin 500&#x000a0;mg, and caffeine 130&#x000a0;mg) with a prescription migraine product (50&#x000a0;mg sumatriptan) in a randomized, controlled clinical trial in which subjects were treated at the first sign of a migraine attack. He concluded that the combination of acetaminophen, aspirin, and caffeine was significantly more effective (<italic>p</italic>&#x000a0;&#x0003e;&#x000a0;0.05) than sumatriptan in the early treatment of migraine, as shown by superiority in summed pain intensity difference, pain relief, pain intensity difference, response, sustained response, relief of associated symptoms, use of rescue medication, disability relief, and global assessments of effectiveness [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p>More recently Diener [<xref ref-type="bibr" rid="CR17">17</xref>] in a post hoc analysis reported that the fixed combination of ASA (250&#x000a0;mg), paracetamol (200&#x000a0;mg), and caffeine (50&#x000a0;mg) is effective and well tolerated in a broad spectrum from mild-to-severe migraine and TTH severity independent of the headache diagnosis.</p><p>Prior confirmed in a double-blind study that acetaminophen 1,000&#x000a0;mg is an effective and well-tolerated treatment for episodic and moderate migraine headache. In addition, acetaminophen generally provided a beneficial effect on associated symptoms of migraine including nausea, photophobia, phonophobia, and functional disability [<xref ref-type="bibr" rid="CR18">18</xref>].</p><p>we some years ago, confirmed the efficacy of the acetaminophen&#x000a0;+&#x000a0;caffeine association in TTH [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p>In fact, paracetamol exerts its analgesic activity through a direct effect on the central nervous system [<xref ref-type="bibr" rid="CR19">19</xref>], at least in part mediated by the serotonergic system [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Due to its scarce inhibition of peripheral cyclooxygenase: it is better tolerated at gastrointestinal level than NSAIDs, it is only a weak inhibitor of platelets aggregation and does not alter the bleeding time [<xref ref-type="bibr" rid="CR22">22</xref>].</p><p>The association with caffeine is relevant because of the well-known antagonism of adenosine A(2A) and A(2B) receptors, as well as the inhibition of cyclooxygenase activity at some sites, may explain intrinsic antinociceptive and adjuvant actions. When combined with morphine, caffeine can augment, inhibit or have no effect depending on the dose, route of administration, nociceptive test, and species. Low doses of caffeine given systemically inhibit antinociception by several analgesics (acetaminophen, amitriptyline, oxcarbazepine, cizolirtine), probably reflecting block of a component of action involving adenosine A(1) receptors. Clinical studies have demonstrated adjuvant analgesia, as well as some intrinsic analgesia, in the treatment of headache conditions, but not in the treatment of post-operative pain [<xref ref-type="bibr" rid="CR23">23</xref>], and Diener [<xref ref-type="bibr" rid="CR24">24</xref>] showed the superiority of the combinations containing caffeine over the association of aspirin and paracetamol alone.</p><p>Because the cross-over there were no differences between groups, but it was interesting to note that males showed a BMI significantly superior to the females (Fisher exact test: <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001).</p><p>Comparing the two treatments, there was a complete overlapping in the efficacy items both for SPID and TOTPAR.</p><p>Analyzing the time course of the mean of pain intensity it is interesting to note that at the 24&#x000a0;h almost all patients had resolved their migraine attacks, whereas 41&#x000a0;% of them should assume a rescue medication.</p><p>Rescue medication was assumed within both treatments without differences, even when we compared the time of assumption: in fact, there was a small and non-significant difference between SUM treatment where patients assumed in the 38&#x000a0;% of cases the rescue drug at the time 3 versus a 21&#x000a0;% of assumption in PCF treatments (Fisher exact test: <italic>p</italic>&#x000a0;=&#x000a0;0.22).</p><p>The evaluation of efficacy and tolerability in the patient&#x02019;s report again showed a complete equivalence of the treatments. In addition, about 80&#x000a0;% of patients for each treatment declared much or complete relief, and a similar percentage referred a very good/excellent tolerability. Even this parameter did not show the differences between the treatments.</p><p>We reported the number of total side effects (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>) and the more frequent types in Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>. In this table, there was a significant increase of fatigue in patients assuming SUM compared with cases assuming PCF: This datum result isvery low in the PCF treatment whereas the % in the SUM treatment is similar to the placebo group in our previous study [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p>In conclusion, this trial could have relevant implications for the clinical practice, showing that the simple combination of paracetamol&#x000a0;1,000 mg&#x000a0;+&#x000a0;caffeine 130&#x000a0;mg seems to be as efficient and safe as sumatriptan 50 mg by mouth, and this could be an important indication for patients suffering from migraine who cannot assume triptans.</p></sec></body><back><ack><p>This work was supported by a grant from the Italian League of Cephalalgic Patients (LIC-Onlus) a no-profit association of patients.</p><sec id="d29e1603"><title>Conflict of interest</title><p>PLA received honoraria for participation in clinical trials, contribution to advisory boards, or oral presentations from: Allergan, Almirall, ACRAF, GlaxoSmithKline, Janssen-Cilag, Guidotti, Pfizer. The other authors did not have conflict of interest with pharmaceutical farm possibly involved to this argument.</p></sec><sec id="d29e1608"><title>Open Access</title><p>This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipton</surname><given-names>RB</given-names></name><name><surname>Bigal</surname><given-names>ME</given-names></name><name><surname>Diamond</surname><given-names>M</given-names></name><etal/></person-group><article-title>Migraine prevalence, disease burden, and the need for preventive therapy</article-title><source>Neurology</source><year>2007</year><volume>68</volume><fpage>343</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000252808.97649.21</pub-id><pub-id pub-id-type="pmid">17261680</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leonardi</surname><given-names>M</given-names></name><name><surname>Steiner</surname><given-names>TJ</given-names></name><name><surname>Scher</surname><given-names>AT</given-names></name><name><surname>Lipton</surname><given-names>RB</given-names></name></person-group><article-title>The global burden of migraine: measuring disability in headache disorders with WHO&#x02019;s Classification of Functioning, Disability and Health (ICF)</article-title><source>J Headache Pain</source><year>2005</year><volume>6</volume><issue>6</issue><fpage>429</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1007/s10194-005-0252-4</pub-id><pub-id pub-id-type="pmid">16388337</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hazard</surname><given-names>E</given-names></name><name><surname>Munakata</surname><given-names>J</given-names></name><name><surname>Bigal</surname><given-names>ME</given-names></name><name><surname>Rupnow</surname><given-names>MF</given-names></name><name><surname>Lipton</surname><given-names>RB</given-names></name></person-group><article-title>The burden of migraine in the United States: current and emerging perspectives on disease management and economic analysis</article-title><source>Value Health</source><year>2009</year><volume>12</volume><fpage>55</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1111/j.1524-4733.2008.00404.x</pub-id><pub-id pub-id-type="pmid">18671771</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Headache Classification Subcommittee of the International Headache Society</collab></person-group><article-title>The International Classification of Headache Disorders: 2nd edition</article-title><source>Cephalalgia</source><year>2004</year><volume>24</volume><issue>Suppl 1</issue><fpage>9</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">14979299</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tfelt-Hansen</surname><given-names>P</given-names></name></person-group><article-title>Acute pharmacotherapy of migraine, tension-type headache, and cluster headache</article-title><source>J Headache Pain</source><year>2007</year><volume>8</volume><fpage>127</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1007/s10194-007-0373-z</pub-id><pub-id pub-id-type="pmid">17497267</pub-id></mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartolini</surname><given-names>M</given-names></name><name><surname>Giamberardino</surname><given-names>MA</given-names></name><name><surname>Lisotto</surname><given-names>C</given-names></name><name><surname>Martelletti</surname><given-names>P</given-names></name><name><surname>Moscato</surname><given-names>D</given-names></name><name><surname>Panascia</surname><given-names>B</given-names></name><name><surname>Savi</surname><given-names>L</given-names></name><name><surname>Pini</surname><given-names>LA</given-names></name><name><surname>Sances</surname><given-names>G</given-names></name><name><surname>Santoro</surname><given-names>P</given-names></name><name><surname>Zanchin</surname><given-names>G</given-names></name><name><surname>Omboni</surname><given-names>S</given-names></name><name><surname>Ferrari</surname><given-names>MD</given-names></name><name><surname>Brighina</surname><given-names>F</given-names></name><name><surname>Fierro</surname><given-names>B</given-names></name></person-group><article-title>A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine</article-title><source>J Headache Pain</source><year>2011</year><volume>12</volume><issue>3</issue><fpage>361</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1007/s10194-011-0325-5</pub-id><pub-id pub-id-type="pmid">21437714</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarchielli</surname><given-names>P</given-names></name><name><surname>Granella</surname><given-names>F</given-names></name><name><surname>Prudenzano</surname><given-names>MP</given-names></name><name><surname>Pini</surname><given-names>LA</given-names></name><name><surname>Guidetti</surname><given-names>V</given-names></name><name><surname>Bono</surname><given-names>G</given-names></name><name><surname>Pinessi</surname><given-names>L</given-names></name><name><surname>Alessandri</surname><given-names>M</given-names></name><name><surname>Antonaci</surname><given-names>F</given-names></name><name><surname>Fanciullacci</surname><given-names>M</given-names></name><name><surname>Ferrari</surname><given-names>A</given-names></name><name><surname>Guazzelli</surname><given-names>M</given-names></name><name><surname>Nappi</surname><given-names>G</given-names></name><name><surname>Sance</surname><given-names>G</given-names></name><name><surname>Sandrini</surname><given-names>G</given-names></name><name><surname>Savi</surname><given-names>L</given-names></name><name><surname>Tassorelli</surname><given-names>C</given-names></name><name><surname>Zanchin</surname><given-names>G</given-names></name></person-group><article-title>Italian guidelines for primary headaches: 2012 revised version</article-title><source>J Headache Pain.</source><year>2012</year><volume>13</volume><issue>Suppl 2</issue><fpage>S31</fpage><lpage>S70</lpage><pub-id pub-id-type="doi">10.1007/s10194-012-0437-6</pub-id><pub-id pub-id-type="pmid">22581120</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelley</surname><given-names>NE</given-names></name><name><surname>Tepper</surname><given-names>DE</given-names></name></person-group><article-title>Rescue therapy for acute migraine, part 3: opioids, NSAIDs, steroids, and post-discharge medications</article-title><source>Headache</source><year>2012</year><volume>52</volume><fpage>467</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.2012.02097.x</pub-id><pub-id pub-id-type="pmid">22404708</pub-id></mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robbins</surname><given-names>M</given-names></name></person-group><article-title>Paracetamol is more effective than placebo for migraine, and paracetamol 1000 mg plus metoclopramide 10 mg is similarly effective to oral sumatriptan 100 mg for migraine relief at 2 h</article-title><source>Evidence Based Med</source><year>2011</year><volume>16</volume><fpage>114</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1136/ebm1201</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Migliardi</surname><given-names>JR</given-names></name><name><surname>Armellino</surname><given-names>JJ</given-names></name><name><surname>Friedman</surname><given-names>M</given-names></name><etal/></person-group><article-title>Caffeine as an analgesic adjuvant in tension headache</article-title><source>Clin Pharmacol Ther</source><year>1994</year><volume>56</volume><fpage>576</fpage><lpage>586</lpage><pub-id pub-id-type="doi">10.1038/clpt.1994.179</pub-id><pub-id pub-id-type="pmid">7955822</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pini</surname><given-names>LA</given-names></name><name><surname>Bene</surname><given-names>E</given-names></name><name><surname>Zanchin</surname><given-names>G</given-names></name><name><surname>Sarchielli</surname><given-names>P</given-names></name><name><surname>Trapani</surname><given-names>G</given-names></name><name><surname>Prudenzano</surname><given-names>MP</given-names></name><name><surname>LaPegna</surname><given-names>G</given-names></name><name><surname>Savi</surname><given-names>L</given-names></name><name><surname>Loreto</surname><given-names>G</given-names></name><name><surname>Dionisio</surname><given-names>P</given-names></name><name><surname>Granella</surname><given-names>F</given-names></name></person-group><article-title>Tolerability and efficacy of a combination of paracetamol and caffeine in the treatment of tension-type headache: a randomized, double-blind, double-dummy, cross-over study versus placebo and naproxen sodium</article-title><source>J Headache Pain</source><year>2008</year><volume>9</volume><fpage>367</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1007/s10194-008-0071-5</pub-id><pub-id pub-id-type="pmid">18815727</pub-id></mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>J</given-names></name><name><surname>Silberstein</surname><given-names>SD</given-names></name><name><surname>Saper</surname><given-names>JR</given-names></name><name><surname>Elkind</surname><given-names>AH</given-names></name><name><surname>Smith</surname><given-names>TR</given-names></name><name><surname>Gallagher</surname><given-names>RM</given-names></name><name><surname>Battikha</surname><given-names>JP</given-names></name><name><surname>Hoffman</surname><given-names>H</given-names></name><name><surname>Baggish</surname><given-names>J</given-names></name></person-group><article-title>Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial</article-title><source>Headache</source><year>2005</year><volume>45</volume><fpage>973</fpage><lpage>982</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.2005.05177.x</pub-id><pub-id pub-id-type="pmid">16109110</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Derosier</surname><given-names>FJ</given-names></name><name><surname>Kori</surname><given-names>SH</given-names></name></person-group><article-title>Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial-a comment</article-title><source>Headache</source><year>2007</year><volume>47</volume><issue>623</issue><fpage>623</fpage><lpage>625</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.2007.00766_1.x</pub-id><pub-id pub-id-type="pmid">17445117</pub-id></mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wenzel</surname><given-names>RG</given-names></name></person-group><article-title>A comment on acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial</article-title><source>Headache</source><year>2006</year><volume>46</volume><issue>341</issue><fpage>341</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.2006.00351_3.x</pub-id><pub-id pub-id-type="pmid">16492251</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>International Headache Society Committee on Clinical Trials</collab></person-group><article-title>Guidelines for controlled trials of drugs in migraine: second edition</article-title><source>Cephalalgia</source><year>2000</year><volume>20</volume><fpage>765</fpage><lpage>786</lpage><pub-id pub-id-type="doi">10.1046/j.1468-2982.2000.00117.x</pub-id><pub-id pub-id-type="pmid">11167908</pub-id></mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipton</surname><given-names>RB</given-names></name><name><surname>Stewart</surname><given-names>WF</given-names></name><name><surname>Ryan</surname><given-names>RE</given-names><suffix>Jr</suffix></name><name><surname>Saper</surname><given-names>J</given-names></name><name><surname>Silberstein</surname><given-names>S</given-names></name><name><surname>Sheftell</surname><given-names>F</given-names></name></person-group><article-title>Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain: three double-blind, randomized, placebo-controlled trials</article-title><source>Arch Neurol</source><year>1998</year><volume>55</volume><fpage>210</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1001/archneur.55.2.210</pub-id><pub-id pub-id-type="pmid">9482363</pub-id></mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diener</surname><given-names>HC</given-names></name><name><surname>Peil</surname><given-names>H</given-names></name><name><surname>Aicher</surname><given-names>B</given-names></name></person-group><article-title>The efficacy and tolerability of a fixed combination of acetylsalicylic acid, paracetamol, and caffeine in patients with severe headache: a post hoc subgroup analysis from a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study</article-title><source>Cephalalgia</source><year>2011</year><volume>31</volume><fpage>1466</fpage><lpage>1476</lpage><pub-id pub-id-type="doi">10.1177/0333102411419682</pub-id><pub-id pub-id-type="pmid">21908446</pub-id></mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prior</surname><given-names>MJ</given-names></name><name><surname>Codispoti</surname><given-names>JR</given-names></name></person-group><article-title>A randomized, placebo-controlled trial of acetaminophen for treatment of migraine headache</article-title><source>Headache</source><year>2010</year><volume>50</volume><fpage>819</fpage><lpage>833</lpage><pub-id pub-id-type="doi">10.1111/j.1526-4610.2010.01638.x</pub-id><pub-id pub-id-type="pmid">20236342</pub-id></mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piletta</surname><given-names>P</given-names></name><name><surname>Porchet</surname><given-names>HC</given-names></name><name><surname>Dayer</surname><given-names>P</given-names></name></person-group><article-title>Central analgesic effect of acetaminophen but not of aspirin</article-title><source>Clin Pharmacol Ther</source><year>1991</year><volume>49</volume><fpage>350</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1038/clpt.1991.40</pub-id><pub-id pub-id-type="pmid">2015724</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pini</surname><given-names>LA</given-names></name><name><surname>Vitale</surname><given-names>G</given-names></name><name><surname>Ottani</surname><given-names>A</given-names></name><etal/></person-group><article-title>Naloxone-reversible antinociception by paracetamol in the rat</article-title><source>J Pharmacol Exp Ther</source><year>1997</year><volume>280</volume><fpage>934</fpage><lpage>940</lpage><pub-id pub-id-type="pmid">9023309</pub-id></mixed-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sandrini</surname><given-names>M</given-names></name><name><surname>Romualdi</surname><given-names>P</given-names></name><name><surname>Capobianco</surname><given-names>A</given-names></name><etal/></person-group><article-title>The effect of paracetamol on nociception and dynorphin A levels in the rat brain</article-title><source>Neuropeptides</source><year>2001</year><volume>35</volume><fpage>110</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1054/npep.2001.0852</pub-id><pub-id pub-id-type="pmid">11384206</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Botting</surname><given-names>RM</given-names></name></person-group><article-title>Mechanism of action of acetaminophen: is there a cyclooxygenase 3?</article-title><source>Clin Infect Dis</source><year>2000</year><volume>31</volume><issue>suppl 5</issue><fpage>S202</fpage><lpage>S210</lpage><pub-id pub-id-type="doi">10.1086/317520</pub-id><pub-id pub-id-type="pmid">11113024</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawynok</surname><given-names>J</given-names></name></person-group><article-title>Methylxanthines and pain</article-title><source>Handb Exp Pharmacol</source><year>2011</year><volume>200</volume><fpage>311</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1007/978-3-642-13443-2_11</pub-id><pub-id pub-id-type="pmid">20859801</pub-id></mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diener</surname><given-names>HC</given-names></name><name><surname>Pfaffenrath</surname><given-names>V</given-names></name><name><surname>Pageler</surname><given-names>L</given-names></name><name><surname>Peil</surname><given-names>H</given-names></name><name><surname>Aicher</surname><given-names>B</given-names></name></person-group><article-title>The fixed combination of acetylsalicylic acid, paracetamol, and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study</article-title><source>Cephalalgia</source><year>2005</year><volume>25</volume><fpage>776</fpage><lpage>787</lpage><pub-id pub-id-type="doi">10.1111/j.1468-2982.2005.00948.x</pub-id><pub-id pub-id-type="pmid">16162254</pub-id></mixed-citation></ref></ref-list></back></article>